Cargando…

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial

OBJECTIVE: To determine the effect of erenumab, a human anti-calcitonin gene-related peptide receptor monoclonal antibody, in patients with chronic migraine and medication overuse. METHODS: In this double-blind, placebo-controlled study, 667 adults with chronic migraine were randomized (3:2:2) to pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tepper, Stewart J., Diener, Hans-Christoph, Ashina, Messoud, Brandes, Jan Lewis, Friedman, Deborah I., Reuter, Uwe, Cheng, Sunfa, Nilsen, Jon, Leonardi, Dean K., Lenz, Robert A., Mikol, Daniel D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598821/ https://www.ncbi.nlm.nih.gov/pubmed/30996056 http://dx.doi.org/10.1212/WNL.0000000000007497

Ejemplares similares

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
por: Ashina, Messoud, et al.
Publicado: (2022)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
por: Tepper, Stewart J, et al.
Publicado: (2021)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials
por: Ashina, Messoud, et al.
Publicado: (2021)

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
por: Hirata, Koichi, et al.
Publicado: (2021)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
por: Takeshima, Takao, et al.
Publicado: (2021)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies
por: Hirata, Koichi, et al.
Publicado: (2022)

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
por: Cullum, Christopher Kjaer, et al.
Publicado: (2022)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
por: Dodick, David W., et al.
Publicado: (2021)

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
por: Diener, HC, et al.
Publicado: (2013)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States
por: Tepper, Stewart J, et al.
Publicado: (2021)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
por: Hong, Ja Bin, et al.
Publicado: (2023)

Risk of medication overuse headache across classes of treatments for acute migraine
por: Thorlund, Kristian, et al.
Publicado: (2016)

Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_32epoh56aa0r6nlf89acf1n5ob